DNLI Stock Risk & Deep Value Analysis
Denali Therapeutics Inc
DVR Score
out of 10
The Bottom Line on DNLI
We analyzed Denali Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran DNLI through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
Get notified when DNLI moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈DNLI Performance Overview3yr weekly
Unlock DNLI Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
DNLI Quality Rating
DNLI Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
DNLI Deep Value Analysis
DNLI Research Sources
No external source links for this analysis yet. Run a fresh analysis to capture SEC filings and financial news articles we used.
For educational context only. Not financial advice.
DNLI Red Flags & Warning Signs
- ⚠
Negative readouts from ongoing DNL151 or DNL310 trials
- ⚠
Slower-than-expected progress or further setbacks for pipeline assets
- ⚠
Increased competitive pressure or superior efficacy data from rivals (e.g., Roche's BBB tech)
Unlock DNLI Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
DNLI Financial Health Metrics
Market Cap
$2.80B
P/E Ratio
-12.34
Profit Margin
-241.00%
Debt-to-Equity
0.03
Dividend Yield
0.00%
Beta (Volatility)
1.42
Earnings Per Share
$-1.47
DNLI Competitive Moat Analysis
Moat Rating
Narrow
Moat Trend
Eroding
Moat Sources
2 Identified
The moat, primarily derived from its BBB platform and pipeline IP, faces increasing pressure. Roche's development of potentially superior brain shuttle technology and the DNL343 trial failure indicate that Denali's competitive edge, while present, is not unassailable and requires consistent execution.
DNLI Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
DNLI Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings (Expected May 7, 2026)
- •Updates on DNL151 (Parkinson's) Phase 2/3 trial progress
Medium-Term (6-18 months)
- •DNL788 (SMA) Phase 3 trial readouts or advancement news
- •DNL310 (MPS II) potential regulatory filings/approvals
- •New strategic partnerships or expanded collaboration terms
Long-Term (18+ months)
- •Commercialization of key neurodegenerative assets (e.g., DNL151) leading to significant revenue generation
- •Broad adoption of the proprietary BBB platform across multiple indications
- •Industry-wide shift towards targeted neurodegenerative therapies
Catalysts & Growth Drivers
Sign up free to see growth catalysts
DNLI Bull Case: What Could Go Right
- ✓
Positive Phase 2/3 trial data readouts for DNL151 or DNL310
- ✓
Expansion of existing partnerships or new collaboration agreements
- ✓
Significant reduction in cash burn rate or clear path to revenue generation from pipeline
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Denali Therapeutics Inc (DNLI)?
As of April 8, 2026, Denali Therapeutics Inc has a DVR Score of 5.4 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Denali Therapeutics Inc?
Denali Therapeutics Inc's market capitalization is approximately $2.8B..
What is the risk level for DNLI stock?
Our analysis rates Denali Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of DNLI?
Denali Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -12.3. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Denali Therapeutics Inc's revenue growing?
Denali Therapeutics Inc has reported revenue growth of -12.0%. Revenue has been declining, which warrants closer examination.
Is DNLI stock profitable?
Denali Therapeutics Inc has a profit margin of -241.0%. The company is currently unprofitable.
How often is the DNLI DVR analysis updated?
Our AI-powered analysis of Denali Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 8, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.